Transplant Rejection: Immune Recognition Failure
Transplant rejection occurs when the recipient’s immune system recognises transplanted tissue as foreign and mounts an immune response against it. Despite careful donor–recipient matching, transplanted organs carry antigens that differ from the host’s own tissues. The immune system is highly efficient at detecting these differences and responding aggressively. Rather than representing immune malfunction, transplant rejection reflects normal immune surveillance applied in an abnormal context. Understanding the underlying mechanisms explains why rejection can occur early, late, or progressively over time.
What You Need to Know
Transplant rejection occurs when the recipient’s immune system recognises the transplanted organ as non-self and mounts an immune response against it. Donor tissues express antigens, particularly human leukocyte antigens, that differ from those of the recipient. These antigens are detected by the innate and adaptive immune systems, leading to activation of immune cells that treat the graft as a foreign target. Once immune recognition occurs, inflammatory and cytotoxic pathways are engaged in much the same way as they would be during infection, but the target is functioning donor tissue rather than a pathogen.
Several overlapping immune processes drive rejection and determine how it presents:
activation of recipient T cells and antibodies against donor antigens
recruitment of inflammatory cells into the graft with vascular and tissue injury
progressive loss of graft function due to immune-mediated damage
Rejection is not a single event but a spectrum of immune responses that differ in timing and mechanism. Some forms occur rapidly when pre-existing antibodies react immediately with donor antigens, while others develop gradually as adaptive immune responses mature over weeks, months, or years. The dominant immune pathway involved influences the pattern of injury, the speed of deterioration, and the response to treatment. Understanding rejection as an immune recognition failure rather than a surgical complication explains why prevention relies on long-term immune modulation and why graft injury can evolve even when early post-transplant recovery appears stable.
Beyond the Basics
Allorecognition: how the immune system identifies the graft
Transplant rejection begins with allorecognition, the process by which the recipient’s immune system identifies donor tissue as foreign. Donor cells express surface antigens, particularly human leukocyte antigens, that differ structurally from those of the recipient. These molecular differences are sufficient to trigger immune activation, even when the graft is healthy and functioning. Recognition occurs through two main pathways. In direct allorecognition, donor antigen-presenting cells within the graft activate recipient T lymphocytes. In indirect allorecognition, recipient antigen-presenting cells process donor antigens and present them to the adaptive immune system.
Once initiated, immune activation persists because donor antigens remain continuously present. Unlike infection, there is no clearance phase that removes the stimulus. This ongoing antigen exposure sustains adaptive immune responses and explains why rejection risk does not diminish completely over time. All forms of rejection originate from this persistent immune recognition, with timing and severity determined by the dominant immune pathways involved.
Hyperacute rejection: immediate antibody-mediated destruction
Hyperacute rejection occurs within minutes to hours of graft reperfusion and is driven by pre-existing antibodies in the recipient. These antibodies recognise donor antigens and bind directly to the vascular endothelium of the graft as soon as blood flow is restored. Antibody binding activates the complement cascade, leading to endothelial injury, platelet aggregation, and widespread thrombosis within graft vessels. Because injury is primarily vascular, perfusion collapses almost immediately. Oxygen and nutrient delivery cease before cellular immune responses can develop, rendering the graft non-viable within a very short timeframe. This form of rejection is catastrophic and irreversible. The mechanism explains the necessity of pre-transplant crossmatching and antibody screening, as once hyperacute rejection occurs, graft removal is unavoidable.
Acute rejection: cell-mediated immune injury
Acute rejection most commonly develops days to weeks after transplantation, though it may occur later if immune suppression is inadequate. It is driven predominantly by T-cell–mediated immune responses. Activated recipient T lymphocytes infiltrate the graft and initiate tissue injury through direct cytotoxic effects and cytokine release. These signals recruit additional immune cells, amplifying inflammation within the graft. Early in acute rejection, tissue architecture may remain largely intact despite functional impairment. This creates a window during which immune modulation can restore graft function. The potential for reversibility distinguishes acute rejection from chronic forms and explains why early detection and timely intervention significantly alter outcomes.
Antibody-mediated components of acute rejection
In some cases, acute rejection includes a significant antibody-mediated component. Newly generated donor-specific antibodies bind to graft endothelium and activate complement pathways. This causes vascular inflammation, capillary injury, and impaired perfusion that compound cellular immune damage. When cellular and antibody-mediated mechanisms occur together, graft injury progresses more rapidly and may respond less predictably to treatment. Vascular injury limits oxygen delivery and accelerates tissue damage, increasing the likelihood of transition to long-term graft dysfunction even if the acute episode is partially controlled.
Chronic rejection: progressive immune-driven graft failure
Chronic rejection develops over months to years through ongoing, low-grade immune activity that never fully resolves. Instead of overt inflammation, immune signalling gradually alters graft structure. Persistent endothelial injury leads to intimal thickening and narrowing of blood vessels, reducing long-term perfusion. Fibroblast activation and extracellular matrix deposition replace functional tissue with scar, progressively impairing organ performance.
Because immune activation continues at a subclinical level, deterioration is often slow and difficult to detect early. Functional decline may only become apparent once significant structural damage has accumulated. At this stage, injury is largely irreversible. This process explains why late graft failure can occur despite apparent short-term stability and why long-term graft survival depends on sustained immune modulation rather than episodic treatment.
Why transplant rejection is inevitable without immune suppression
Transplant rejection occurs because the immune system is performing its core function of identifying and responding to non-self antigens. Any tissue expressing foreign antigens will activate adaptive immune pathways once recognition occurs. Without immune modulation, this activation persists because donor antigens remain permanently present within the graft. Immune suppression limits immune cell activation, proliferation, and persistence rather than eliminating graft recognition entirely. This balance reduces tissue injury enough to allow graft survival but does not remove rejection risk. Changes in immune thresholds, medication adherence, or immune activation can re-ignite rejection even years after transplantation. Transplantation therefore represents a sustained state of managed immune conflict that requires continuous modulation to preserve graft structure and function over time.
Clinical Connections
Transplant rejection often presents with subtle or non-specific features, particularly in early or chronic forms. Immune-mediated injury begins within the graft vasculature and parenchyma, so deterioration in graft function frequently precedes systemic symptoms. Acute rejection typically causes a relatively rapid decline in graft performance, whereas chronic rejection progresses slowly with gradual loss of functional reserve. Structural injury can advance before overt clinical signs are evident, making delayed recognition a major contributor to irreversible graft damage.
Long-term graft survival depends on continuous immune suppression. Anti-rejection medications do not eliminate immune recognition of the graft but reduce immune cell activation, proliferation, and persistence. Because donor antigens remain permanently present, interruption, under-dosing, or altered absorption of these medications allows immune activity to re-emerge. Even brief lapses in therapy can permit immune activation that initiates graft injury, which may continue despite later correction.
Several clinical patterns are closely linked to long-term immune suppression:
gradual changes in graft function that coincide with medication non-adherence, interactions, or altered pharmacokinetics
increased susceptibility to infection or malignancy due to reduced immune surveillance
laboratory abnormalities related to drug toxicity that may complicate assessment of graft dysfunction
Ongoing care therefore centres on vigilant monitoring of graft function, immune suppression levels, and treatment-related complications over time. Assessment integrates functional trends, laboratory data, and medication history rather than relying on symptoms alone. Maintaining the balance between preventing immune-mediated graft injury and limiting complications of chronic immune suppression is central to preserving long-term graft function and patient outcomes.
Concept Check
What is allorecognition, and why is it central to transplant rejection?
Why does hyperacute rejection occur so rapidly and irreversibly?
How does acute rejection differ mechanistically from chronic rejection?
Why can acute rejection sometimes be reversed while chronic rejection cannot?
Why does rejection risk persist long after transplantation?